BSE Live
Apr 17, 16:01Prev. Close
748.90
Open Price
749.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 17, 15:58Prev. Close
748.30
Open Price
753.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
784.75 (13)
| Key Financial Ratios of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 15.01 | 12.49 | 8.77 | 6.90 | 4.53 | |
| Diluted EPS (Rs.) | 15.01 | 12.49 | 8.77 | 6.90 | 4.53 | |
| Cash EPS (Rs.) | 17.35 | 14.64 | 10.62 | 8.69 | 20.91 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 46.43 | 35.09 | 26.32 | 20.66 | 48.83 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 46.43 | 35.09 | 26.32 | 20.66 | 48.83 | |
| Revenue from Operations/Share (Rs.) | 109.07 | 98.84 | 80.65 | 77.79 | 218.55 | |
| PBDIT/Share (Rs.) | 21.50 | 19.14 | 13.57 | 11.71 | 29.15 | |
| PBIT/Share (Rs.) | 19.14 | 17.00 | 11.72 | 9.93 | 23.77 | |
| PBT/Share (Rs.) | 19.05 | 16.48 | 10.95 | 8.54 | 19.43 | |
| Net Profit/Share (Rs.) | 15.00 | 12.49 | 8.77 | 6.90 | 15.53 | |
| NP After MI And SOA / Share (Rs.) | 15.01 | 12.49 | 8.77 | 6.90 | 15.53 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 19.71 | 19.37 | 16.83 | 15.06 | 13.33 | |
| PBIT Margin (%) | 17.55 | 17.19 | 14.53 | 12.76 | 10.87 | |
| PBT Margin (%) | 17.46 | 16.67 | 13.57 | 10.97 | 8.88 | |
| Net Profit Margin (%) | 13.75 | 12.63 | 10.86 | 8.87 | 7.10 | |
| NP After MI And SOA Margin (%) | 13.76 | 12.63 | 10.86 | 8.87 | 7.10 | |
| Return on Networth/Equity (%) | 32.32 | 35.60 | 33.30 | 33.40 | 31.79 | |
| Return on Capital Employed (%) | 29.56 | 30.58 | 27.26 | 25.16 | 19.07 | |
| Return on Assets (%) | 17.23 | 19.33 | 15.77 | 12.37 | 10.12 | |
| Total Debt/Equity (X) | 0.27 | 0.12 | 0.28 | 0.60 | 1.02 | |
| Asset Turnover Ratio (%) | 125.28 | 152.99 | 145.09 | 139.40 | 142.48 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.30 | 1.69 | 1.43 | 1.29 | 1.35 | |
| Quick Ratio (X) | 0.74 | 0.99 | 0.83 | 0.80 | 0.80 | |
| Inventory Turnover Ratio (X) | 5.37 | 6.00 | 5.70 | 5.67 | 5.48 | |
| Dividend Payout Ratio (NP) (%) | 23.32 | 24.81 | 28.51 | 20.28 | 22.07 | |
| Dividend Payout Ratio (CP) (%) | 20.15 | 21.17 | 23.53 | 16.11 | 16.39 | |
| Earnings Retention Ratio (%) | 76.68 | 75.19 | 71.49 | 79.72 | 77.93 | |
| Cash Earnings Retention Ratio (%) | 79.85 | 78.83 | 76.47 | 83.89 | 83.61 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 202.68 | 32.67 | 15.16 | 7.14 | 5.47 | |
| Interest Coverage Ratios (Post Tax) (%) | 202.68 | 32.67 | 15.16 | 7.14 | 5.47 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 8,756.16 | 5,404.71 | 2,087.94 | 1,099.65 | 0.00 | |
| EV/Net Operating Revenue (X) | 4.26 | 2.90 | 1.37 | 0.75 | 0.00 | |
| EV/EBITDA (X) | 21.61 | 14.98 | 8.16 | 4.98 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 4.16 | 2.87 | 1.29 | 0.62 | 0.00 | |
| Retention Ratios (%) | 76.67 | 75.18 | 71.48 | 79.71 | 77.92 | |
| Price/BV (X) | 9.76 | 8.09 | 3.96 | 2.34 | 0.00 | |
| Price/Net Operating Revenue | 4.16 | 2.87 | 1.29 | 0.62 | 0.00 | |
| Earnings Yield | 0.03 | 0.04 | 0.08 | 0.14 | 0.00 |
19.02.2026
18.02.2026
Alembic Pharma Consolidated December 2025 Net Sales at Rs 1,876.31 crore, up 10.84% Y-o-Y
09.02.2026
Alembic Pharma Standalone December 2025 Net Sales at Rs 1,642.24 crore, up 16.79% Y-o-Y
17.11.2025
Alembic Pharma shares gain 2% on USFDA nod for Diltiazem Hydrochloride tablets
18.02.2026
Alembic Pharma Consolidated December 2025 Net Sales at Rs 1,876.31 crore, up 10.84% Y-o-Y
09.02.2026
Alembic Pharma Standalone December 2025 Net Sales at Rs 1,642.24 crore, up 16.79% Y-o-Y
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth